Topic: liver cancer


7. Pexa-Vec

Given that backdrop of optimism in the oncolytic virus therapy category, the decision by French biotech Transgene and partner SillaJen to halt a trial of their oncolytic virus candidate Pexa-Vec (pexastimogene devacirepvec) in liver cancer was a warning about the potential pitfalls of this approach.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.